Oxford University Hospitals (OUH) NHS Foundation Trust has signed a strategic research agreement (SRA) with British clinical AI company Sensyne Health to work on ways of improving patient care and accelerating medical research.
It builds on an existing relationship from July 2017 and will involve analysing genetic data that has been anonymised and for which consent has been given to use in research.
The agreement covers data generated by the trust over the past five years and any produced over the next 10.
The two parties also plan to develop a proposal to use genomic medicine, including whole genome sequencing, which when mobilised could be part of the standard pathway of care for the trust’s NHS patients in the future. This would involve using clinical AI to analyse genotypic and clinical data.
They said the research will comply with NHS requirements on information governance and data security and data protection legislation. Genome sequencing will only be undertaken with patient consent for research.
OUH will also receive £5 million in equity in Sensyne Health and a share of royalties that come from any discoveries.
Lord Paul Drayson, chief executive officer of Sensyne Health, commented: “Sensyne Health is developing, in collaboration with the University of Oxford and Oxford University Hospitals, world leading capability in the use of clinical AI to analyse anonymised patient data.
“This new agreement, enabling the analysis of linked genotypic and phenotypic data, will further enhance our ability to make new discoveries and develop new treatments.”
Image by greyloch, CC BY 2.0 through flickr
